drugset / Trial / NCT01629966

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder

NCT01629966

Phase 3 Completed 680 enrolled Forest Laboratories
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)

Timeline

Start
2012-06-30
Primary completion
2014-02-28
Completion
2014-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilazodone Small molecule 20 mg Oral
Subject Vilazodone Small molecule 40 mg Oral